ArticleEJHaem2021

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Jeanette Lundin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.